دورية أكاديمية
Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience.
| العنوان: | Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. |
|---|---|
| المؤلفون: | Abdelaziz H; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt.; Hepatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Omar H; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt., Khalil M; Infectious Disease Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt., Cordie A; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt.; Kasr Alainy Hiv and Viral Hepatitis Fighting Group Cairo Egypt., Mohamed R; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt.; Kasr Alainy Hiv and Viral Hepatitis Fighting Group Cairo Egypt., AbdAllah M; Medical Research Division, National Research Center, Cairo, Egypt., Abdel Maksoud MH; Tropical Medicine Department, Embaba Fever Hospital, Cairo, Egypt., El Garhy N; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt., Ali L; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt., El Serafy M; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt., Esmat G; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt., Doss W; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Giza, Egypt. |
| المصدر: | Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2022 May; Vol. 20 (5), pp. 789-795. Date of Electronic Publication: 2021 Nov 25. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101181284 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8336 (Electronic) Linking ISSN: 14787210 NLM ISO Abbreviation: Expert Rev Anti Infect Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Future Drugs Ltd. |
| مواضيع طبية MeSH: | Coinfection*/drug therapy , HIV Infections*/complications , HIV Infections*/drug therapy , HIV Infections*/epidemiology , Hepatitis C*/complications , Hepatitis C*/drug therapy , Hepatitis C*/epidemiology , Hepatitis C, Chronic*/complications , Hepatitis C, Chronic*/drug therapy , Hepatitis C, Chronic*/epidemiology, Antiviral Agents ; Egypt/epidemiology ; Hepacivirus ; Humans ; Retrospective Studies ; Sofosbuvir ; Treatment Outcome |
| مستخلص: | Background: Liver disease has emerged as a leading cause of death among PLHIV coinfected with HCV. Methods: A retrospective study involving all HCV viremic patients coinfected with HIV who presented to HCV/HIV multidisciplinary clinics located at Embaba fever hospital. Patients were assigned to receive DAAs according to the national treatment guidelines. The primary endpoint was SVR12. Results: Of the 519 patients enrolled, 38.73% LTFU; either not initiated (n = 170) or did not complete the treatment (n = 31). The main identified reasons behind LTFU were schedule conflict (19%) or hospitalization (13%). Among 318 patients who completed their DAAs course, nine patients had a relapse after the end of treatment and 97% had attained SVR12. There were significant differences among different virological response groups in baseline factors including smoking (p = 0.005), history of dental procedure (p = 0.007), CD4 count (p = 0.007), and HIV viral load (p = <0.001). Among responders (n = 309), there was a significant reduction of baseline hemoglobin and significant improvement of baseline platelets (p = 0.005) at on-treatment week 8. Baseline necro-inflammatory markers showed significant improvement across follow-up time points (p < 0.001). Conclusions: DAAs are an effective and safe choice to treat HCV in PLHIV. Social stigma could be a major cause for lacking adherence to follow-up visits. Abbreviations: ALT: Alanine Aminotransferase; ARV: Antiretroviral treatment; AST: Aspartate Aminotransferase; DAAs: Direct acting antivirals; ARVs: antiretroviral therapy; EMR: Eastern Mediterranean region; HCV: Hepatitis C virus; kPa: Kilopascal; LTFU: Patient lost to follow up; NCCVH: The National Committee for Control of Viral Hepatitis; PWID: People who inject drugs; SVR: Sustained virological response;UNAIDS: The Joint United Nations Programme on HIV/AIDS. |
| فهرسة مساهمة: | Keywords: Daclatasvir; HCV; HIV; Real-world; Sofosbuvir |
| المشرفين على المادة: | 0 (Antiviral Agents) WJ6CA3ZU8B (Sofosbuvir) |
| تواريخ الأحداث: | Date Created: 20211109 Date Completed: 20220502 Latest Revision: 20220601 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1080/14787210.2022.2004117 |
| PMID: | 34751609 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8336 |
|---|---|
| DOI: | 10.1080/14787210.2022.2004117 |